East Norriton-based Tmunity Therapeutics, a private clinical-stage biotherapeutics company focused on next-generation T-cell immunotherapy, recently entered into a partnership with Oncora Medical.
Tmunity will use Oncora’s data platform to support the design of future clinical programs for cell therapy and ensure patients are treated more efficiently.
The data platform is a suite of intuitive analytics software that collects and deploys real-world clinical data. The software can be used to create treatment options and better decision-making to improve patient outcomes.
“Partnering with Oncora Medical to utilize real-world data in clinical development puts Tmunity at the forefront of innovation,” Usman Azam, MD, Tmunity president and CEO, said. “This project has the potential to help us more effectively design and execute our clinical trials to advance the next-generation of CAR-T therapies. We are excited to begin our relationship with Oncora Medical to revolutionize the way clinical trials are designed with the ultimate goal of reducing the time to deliver targeted T-cell therapies to patients in need.”
Oncora believes real-world data has the potential to change the way cancer therapies are developed, David Lindsay, Oncora Medical co-founder and CEO, said.
The company hopes the partnership will innovate the way clinical trials are designed.